Evidence map›Paper›PMID 32269052›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2020

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8

Renata Ferrarotto, Diana Bell, Maria L Rubin, Katherine A Hutcheson, Jason M Johnson, Ryan P Goepfert, Jack Phan, Yasir Y Elamin, Danice K Torman, Carla L Warneke and 9 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 6 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Distinct CD8Cancer cell · 2025
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  19. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  20. Trial

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Renata FerrarottoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. rferrarotto@mdanderson.org.ORCID 0000-0002-3561-215X
Diana BellDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria L RubinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Katherine A HutchesonDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3710-5706
Jason M JohnsonDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7724-5784
Ryan P GoepfertDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jack PhanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yasir Y ElaminDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Danice K TormanDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Carla L WarnekeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5012-2861
Amy C HesselDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Adam S GardenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4767-3408
Faye M JohnsonDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2862-4160
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew G SikoraDepartment of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.
Maura L GillisonDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bonnie S GlissonDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Neil D GrossDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9427-0743
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NCI NIH HHS P30 CA016672NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

purposeIn oropharyngeal squamous cell carcinoma (OPC), high CD8 PATIENTS AND

methodsPatients with newly diagnosed stage II-IVA OPC or locoregionally recurrent OPC amenable to resection were included. Patients were randomized to two cycles of durvalumab or durvalumab + tremelimumab before surgery. The primary endpoint was change between baseline and resection specimen in CD8

resultsOf 28 eligible patients (14/arm), 20 (71%) had newly diagnosed OPC, and 24 (86%) were p16-positive. The posttreatment to pretreatment median CD8

conclusionsDurvalumab + tremelimumab did not increase CD8

Indexed as

Lymphocyte CountAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCD8-Positive T-LymphocytesDisease ProgressionFemaleHumansImmunohistochemistryMaleNeoadjuvant TherapyOropharyngeal NeoplasmsQuality of LifeRisk FactorsTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkers, Tumordurvalumabtremelimumab

Identifiers

PMID32269052
PMCPMC8362306
OpenAlexW3015604629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.